Zepto Life Technology Unveils FungiFlex Mold Panel
Zepto Life Technology has introduced an innovative plasma-based test known as the FungiFlex Mold Panel. This advancement allows for faster and noninvasive testing for individuals at risk of invasive fungal infections (IFIs). Offered through a CLIA-certified reference laboratory, this diagnostic tool marks a significant stride in the realm of fungal infection diagnostics.
Understanding the FungiFlex Mold Panel
The FungiFlex Mold Panel is designed to detect cell-free DNA (cfDNA) from 14 clinically relevant mold species using a single plasma sample. Featuring pathogens such as Aspergillus and Mucorales, this test provides results in under 24 hours after receiving the sample. It's important to note that the FungiFlex Mold Panel is not only a breakthrough in diagnostic speed but also represents the first of several upcoming innovations from Zepto's molecular diagnostic platform aimed at infectious diseases.
Importance of Rapid Diagnostic Testing
Invasive fungal infections often plague immunocompromised patients, making timely and accurate diagnosis crucial. Traditionally, diagnosing these infections can be laborious, requiring invasive and expensive procedures that prolong the time to treatment. In contrast, the blood-based molecular approach offered by FungiFlex provides critical clinical insights without the need for invasive sampling.
Clinical Impact of the FungiFlex Mold Panel
Hannah Zhang, CEO of Zepto Life Technology, emphasized the urgency of timely diagnosis in managing invasive fungal infections. "Delayed diagnosis remains one of the biggest challenges in managing these infections," she highlighted. The launch of the FungiFlex Mold Panel as a reference laboratory test represents a proactive move to meet this challenge head-on, enabling quicker detection of infections.
Who Can Benefit from the FungiFlex Mold Panel?
This diagnostic test is primarily aimed at patients exhibiting symptoms or medical conditions that may predispose them to invasive fungal diseases. This includes those undergoing significant medical treatments such as organ transplants or receiving immunosuppressive therapies. Each test sample will be processed in Zepto Life Technology's certified laboratory, ensuring high-quality diagnostics.
About Zepto Life Technology
Zepto Life Technology is focused on pioneering rapid liquid biopsy platforms for infectious diseases, starting with invasive fungal infections. Their goal is to provide actionable diagnostic information derived from simple blood tests, which can be scaled to address various infectious diseases as the company grows.
Media Inquiries and Contact Information
For more information, please contact:
Daphne Yuan
Press Office, Zepto Life Technology
(651) 243-1888
Frequently Asked Questions
What is the FungiFlex Mold Panel?
The FungiFlex Mold Panel is a plasma-based molecular diagnostic test designed to detect specific mold species related to invasive fungal infections.
How quickly can I expect results from the test?
Results from the FungiFlex Mold Panel are typically available within 24 hours of sample receipt.
Who is eligible to take the FungiFlex Mold Panel test?
The test is intended for patients who show symptoms or have conditions that predispose them to fungal infections, especially immunocompromised individuals.
What advantages does this test offer over traditional methods?
This test provides a noninvasive alternative to traditional diagnostic methods, which often require invasive procedures and prolonged waiting times.
What is the vision of Zepto Life Technology?
Zepto Life Technology aims to enhance infectious disease diagnosis through rapid and accessible blood-based testing platforms, improving patient care outcomes.
